Completed NA INTERVENTIONAL 1-arm NCT01370135

Study to Evaluate the Effects of Ranibizumab (Lucentis) for Patients With Rubeosis and Neovascular Glaucoma (LucNVG0108)

An Open Label, Prospective, Monocenter, Prove of Concept Study to Evaluate the Short- and Long-term Effects of 0.5mg Intraocular Ranibizumab (Lucentis) Injections as Adjuvant for Patients With Rubeosis and Neovascular Glaucoma

Sponsor: University of Luebeck

Conditions Neovascular Glaucoma Rubeosis

Interventions 0.5mg intraocular Ranibizumab (Lucentis)

Updated 5 times since 2017 Last updated: Jan 15, 2013 Started: Nov 30, 2008 Primary completion: Apr 30, 2011 Completion: Jul 31, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01370135, this NA trial focuses on Neovascular Glaucoma and Rubeosis and remains completed. Sponsored by University of Luebeck, it has been updated 5 times since 2008, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Jun 2018 — Jan 2021 [monthly]

Completed NA
Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Nov 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

University of Luebeck

Data source: University of Luebeck

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Lübeck, Germany